Valuation: Novavax, Inc.

Market Cap 1.56B 1.36B 1.25B 1.16B 2.21B 148B 2.24B 15.04B 5.85B 72.86B 5.84B 5.71B 252B P/E 2026 *
-20x
P/E 2027 * -37.2x
Enterprise Value 1.77B 1.55B 1.43B 1.33B 2.52B 168B 2.56B 17.16B 6.67B 83.12B 6.66B 6.52B 287B EV / Sales 2026 *
4.33x
EV / Sales 2027 * 7.19x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.18%
1 week+0.42%
Current month+0.42%
1 month-0.32%
3 months+18.55%
6 months+24.15%
Current year+40.77%
1 week 8.88
Extreme 8.885
10.12
1 month 8.26
Extreme 8.265
10.12
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Director

37,760 0.0230%
06-20Fiscal year

Chairman

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%+0.42%+43.12%+30.84% 1.56B
-0.24%+5.24%+2.94%+9.41% 49.74B
+0.25%+1.70%+419.39%+621.71% 40.49B
-0.16%+8.42%+28.20%+63.00% 34.35B
+1.10%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
-0.35%+0.09% - - 16.58B
-3.33%+3.15%+71.30%+131.94% 15.6B
+3.79%+8.88%+106.63%+106.63% 14.27B
-1.28%-0.58%+14.04%+19.53% 13.76B
Average +0.23%+3.83%+79.88%+112.56% 24.81B
Weighted average by Cap. +0.19%+4.56%+95.50%+140.30%

Financials

2026 *2027 *
Net sales 410M 359M 331M 306M 582M 38.91B 591M 3.96B 1.54B 19.2B 1.54B 1.51B 66.37B 258M 226M 208M 193M 367M 24.53B 373M 2.5B 972M 12.11B 970M 949M 41.85B
Net income -79.31M -69.4M -63.96M -59.28M -113M -7.53B -114M -767M -298M -3.71B -298M -291M -12.84B -43.22M -37.82M -34.86M -32.31M -61.33M -4.1B -62.32M -418M -163M -2.02B -162M -159M -7B
Net Debt 219M 192M 177M 164M 311M 20.78B 316M 2.12B 824M 10.26B 822M 804M 35.46B 303M 265M 245M 227M 430M 28.78B 437M 2.93B 1.14B 14.2B 1.14B 1.11B 49.09B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
07/07/26 $9.460 +1.18% 4,517,345
06/07/26 $9.350 -4.00% 2,958,090
02/07/26 $9.740 +2.96% 4,850,708
01/07/26 $9.460 +0.42% 4,568,968
30/06/26 $9.420 +0.64% 3,984,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.460USD
Average target price
14.11USD
Spread / Average Target
+49.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock